Literature DB >> 15382064

HLA-DRB alleles are differentially expressed by tumor cells in breast carcinoma.

Sharon A Oldford1, J Desmond Robb, Peter H Watson, Sheila Drover.   

Abstract

The biologic and prognostic significance of HLA-DR expression and T-cell infiltration in breast carcinoma are presently controversial. To test the hypothesis that these factors are influenced by particular HLA-DRB alleles, 52 breast tumor samples, composed of 26 DRB1*04 and 26 non-DRB1*04 tumors, were assessed using immunohistochemistry for expression of DR and its associated invariant chain (Ii) and for infiltrating CD3+ T cells. While DR expression by tumor cells was significantly associated with T-cell infiltration, DRB1*04 tumors were more frequently DR+ Ii+ and contained smaller CD3+ infiltrates than non-DRB1*04 tumors. This difference was largely attributable to DRB1*07 tumors, which were typically DR- Ii-, although they contained similar numbers of T cells to DR+ Ii+ tumors. Further analysis of DR+ tumors using allotype discriminating antibodies revealed that DRB1*04 alleles were always expressed, while non-DRB1*04 alleles were inconsistently expressed. The results of this study provide the first reported evidence that DRB alleles influence DR expression and T-cell infiltration in breast carcinoma and suggest that multiple factors contribute to DR expression. Ongoing studies aimed at elucidating the molecular and immunologic mechanisms controlling differential DR expression and implications for prognosis and outcome should further our understanding of the antitumor immune response and evasion strategies employed by tumor cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15382064     DOI: 10.1002/ijc.20441

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

Review 1.  Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.

Authors:  Margaret L Axelrod; Rebecca S Cook; Douglas B Johnson; Justin M Balko
Journal:  Clin Cancer Res       Date:  2018-11-21       Impact factor: 12.531

Review 2.  MHC heterogeneity and response of metastases to immunotherapy.

Authors:  Ignacio Algarra; Federico Garrido; Angel M Garcia-Lora
Journal:  Cancer Metastasis Rev       Date:  2021-04-15       Impact factor: 9.264

Review 3.  Antigen processing and immune regulation in the response to tumours.

Authors:  Emma Reeves; Edward James
Journal:  Immunology       Date:  2016-10-12       Impact factor: 7.397

Review 4.  Engineering universal cells that evade immune detection.

Authors:  Robert Lanza; David W Russell; Andras Nagy
Journal:  Nat Rev Immunol       Date:  2019-08-15       Impact factor: 53.106

5.  Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.

Authors:  Jacques Thibodeau; Marie-Claude Bourgeois-Daigneault; Réjean Lapointe
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

6.  Low GILT Expression is Associated with Poor Patient Survival in Diffuse Large B-Cell Lymphoma.

Authors:  Hannah Phipps-Yonas; Haiyan Cui; Noemi Sebastiao; Patrick S Brunhoeber; Ellen Haddock; Martin J Deymier; Wolfram Klapper; Lonnie Lybarger; Denise J Roe; Karen Taraszka Hastings
Journal:  Front Immunol       Date:  2013-12-04       Impact factor: 7.561

7.  CD74 and intratumoral immune response in breast cancer.

Authors:  Zhi-Qiang Wang; Katy Milne; John R Webb; Peter H Watson
Journal:  Oncotarget       Date:  2017-02-21

8.  Spatially-resolved quantification of proteins in triple negative breast cancers reveals differences in the immune microenvironment associated with prognosis.

Authors:  Rachel L Stewart; Anna P Matynia; Rachel E Factor; Katherine E Varley
Journal:  Sci Rep       Date:  2020-04-20       Impact factor: 4.379

9.  Activation of ERα signaling differentially modulates IFN-γ induced HLA-class II expression in breast cancer cells.

Authors:  Ahmed A Mostafa; Dianne Codner; Kensuke Hirasawa; Yumiko Komatsu; Matthew N Young; Viktor Steimle; Sheila Drover
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

10.  BoLA-DRB3 Polymorphism is Associated with Differential Susceptibility to Bovine Leukemia Virus-Induced Lymphoma and Proviral Load.

Authors:  Chieh-Wen Lo; Liushiqi Borjigin; Susumu Saito; Koya Fukunaga; Etsuko Saitou; Katsunori Okazaki; Tetsuya Mizutani; Satoshi Wada; Shin-Nosuke Takeshima; Yoko Aida
Journal:  Viruses       Date:  2020-03-22       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.